Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Some QOL benefits for second-line Halaven in breast cancer

This article was originally published in Scrip

Executive Summary

Eisai has presented new quality of life (QOL) data from one of the main Phase III trials with its breast cancer drug Halaven (eribulin mesylate) that it will be hoping may boost the competitive position of the novel microtubule dynamics inhibitor in the earlier line treatment of metastatic disease.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC021596

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel